Sumac capsules enter a triple-blind test for heavy menstrual bleeding
Hypermenorrhea sits at the intersection of symptom burden, anemia risk, and treatment dissatisfaction. The new protocol from Babol University of Medical Sciences moves Rhus coriaria—better known as sumac—into a randomized, placebo-controlled trial designed to measure whether the herbal product can reduce menstrual blood loss in women with hypermenorrhea.
The study is built around a simple clinical question: can a traditional astringent remedy do what patients and clinicians need most, namely reduce bleeding without adding the side effects or contraindications that often complicate hormonal therapy? The protocol does not claim an answer yet. It lays out the framework for testing one.
Why heavy menstrual bleeding still pushes clinicians toward imperfect options
Abnormal menstrual bleeding remains a common gynecologic problem, and the clinical consequences are familiar: iron deficiency, pain, fatigue, and disruption of daily life. In more severe cases, excess blood loss can contribute to anemia and broader physiologic instability, including coagulopathy, acidosis, hypothermia, and coagulation abnormalities. Structural uterine disease, ovulatory dysfunction, pregnancy-related disorders, and neoplasms can all sit behind the same symptom pattern, which means the bleeding itself is often only the visible part of a larger pathologic process.
Conventional treatment remains effective for many patients, but it is not always well tolerated or appropriate. Nonsteroidal anti-inflammatory drugs, hormone therapy, progestins, and progesterone-releasing intrauterine devices are standard first-line options; hysterectomy and endometrial ablation are reserved for refractory cases. In day-to-day practice, that treatment ladder leaves room for alternatives that are accessible, inexpensive, and acceptable to patients who prefer nonhormonal approaches.
Sumac has been used in Persian medicine for that reason. Traditional texts describe it as cooling and astringent, and modern phytochemical work has identified tannins and flavonoids that offer a biologic rationale for hemostatic activity. Astringency is not a decorative concept here. Compounds with this profile can plausibly promote tissue contraction and help curb capillary oozing, which makes the herb a credible candidate for a bleeding disorder if the clinical effect proves real.
How the trial is structured to separate signal from ritual
Investigators plan a triple-blind, parallel-group, randomized, placebo-controlled trial involving 60 women aged 18 to 45 years. Eligibility requires a Pictorial Blood Loss Assessment Chart score of at least 100, anchoring the study in a population with objectively defined heavy bleeding rather than vague menstrual discomfort.
Participants will receive either a 500 mg sumac capsule twice daily during the first 7 days of menstruation or an Avicel placebo capsule, and the regimen will continue across three consecutive menstrual cycles. The design matters because menstrual blood loss varies from cycle to cycle. A single-cycle snapshot can be misleading; three cycles give the intervention a fairer test and reduce the chance that a random good or bad month drives the result.
The protocol’s triple-blind structure also strengthens the internal validity of the study. When participants, clinicians, and outcome assessors remain unaware of group assignment, expectation effects and measurement bias become harder to smuggle into the findings. In a symptom-driven condition like heavy menstrual bleeding, that protection is essential.
The PBAC endpoint will decide whether the herb has clinical weight
The central outcome is menstrual blood loss, captured through PBAC scoring. In practical terms, this keeps the trial focused on the endpoint that matters most to patients: less bleeding. If sumac works, the benefit should show up in the diary, the sanitary product count, and the overall bleeding score rather than in abstract surrogate measures.
A one-sentence reality check belongs here. Herbal tradition alone does not stop uterine bleeding.
The protocol does not provide efficacy results, and it does not promise safety data beyond what the eventual trial will measure. It does, however, establish a clear framework for observing both benefit and tolerability in a controlled setting. Because the intervention is limited to the first 7 days of menstruation, the study also reflects how a practical adjunct might actually be used in the clinic rather than as a continuous daily medication.
What the protocol can and cannot tell clinicians today
The strongest feature of the study is its effort to generate higher-level evidence for a remedy rooted in traditional Iranian medicine. The treatment sequence described in those traditions begins with lifestyle adjustment, then moves through pharmacologic and procedural options when necessary. Sumac fits within the herbal astringent branch of that sequence, alongside agents such as quince paste, myrtle, pomegranate flower, and plantain.
Yet clinical plausibility is not clinical proof. The protocol itself is the point at which hypothesis becomes testable rather than persuasive. If the trial shows a reduction in PBAC scores, sumac could emerge as a low-cost option for women seeking a complementary approach to heavy menstrual bleeding. If the difference is small or absent, the study will still have performed an important service by narrowing the space between traditional claims and measured effect.
The trial registration number, IRCT20180218038783N12, and the stated registration date of October 5, 2025, place the project in the public record before results are known. No specific funding supported the work, and the investigators declared no competing interests. Those details do not determine efficacy, but they do frame the study as an attempt to bring an old remedy into a modern evidentiary structure.
For now, the unanswered question is not whether sumac has a place in Persian medical history. It is whether a 500 mg capsule, taken twice daily at the start of menstruation, can meaningfully reduce bleeding enough to matter to patients living with hypermenorrhea.